Litcius/Paper detail

Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective

Qiangsheng Zhu, Nannan Chen, Xinjian Tian, Ye-Ling Zhou, Qidong You, Xiaoli Xu

2022Journal of Medicinal Chemistry52 citationsDOIOpen Access PDF

Abstract

Hematopoietic progenitor kinase 1 (HPK1), a hematopoietic cell-restricted member of the serine/threonine Ste20-related protein kinases, is a negative regulator of the T cell receptor, B cell receptor, and dendritic cells. Loss of HPK1 kinase function increases cytokine secretion and enhances T cell signaling, virus clearance, and tumor growth inhibition. Therefore, HPK1 is considered a promising target for tumor immunotherapy. Several HPK1 inhibitors have been reported to regulate T cell function. In addition, HPK1-targeting PROTACs, which can induce the degradation of HPK1, have also been developed. Here, we provide an overview of research concerning HPK1 protein structure, function, and inhibitors and propose perspectives and insights for the future development of agents targeting HPK1.

Topics & Concepts

Cell biologyChemistryCancer researchKinaseImmunotherapyBiologyImmunologyImmune systemProtein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsCAR-T cell therapy research
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective | Litcius